Application Nr Approved Date Route Status External Links
NDA022522 2011-02-28 Oral RX Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Daliresp® Is Indicated As A Treatment To Reduce The Risk Of Copd Exacerbations In Patients With Severe Copd Associated With Chronic Bronchitis And A History Of Exacerbations. Daliresp Is A Selective Phosphodiesterase 4 Inhibitor Indicated As A Treatment To Reduce The Risk Of Copd Exacerbations In Patients With Severe Copd Associated With Chronic Bronchitis And A History Of Exacerbations. (1, 14) Limitations Of Use: Daliresp Is Not A Bronchodilator And Is Not Indicated For The Relief Of Acute Bronchospasm. (1, 14) Limitations Of Use Daliresp Is Not A Bronchodilator And Is Not Indicated For The Relief Of Acute Bronchospasm.

All Formulated Excipients (3 Total)

Name Structure Kind Function Status
1. Lactose Monohydrate LACTOSE MONOHYDRATE Molecular
2. Starch, Corn STARCH, CORN Unresolved
3. Povidones POVIDONES Unresolved

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Roflumilast ROFLUMILAST ZINC592419

Comments